Table 2.
Chemoradiotherapy-induced alterations of the proportion of each circulating lymphocyte subpopulation for all patients
| Variables | Baseline | Post-CRT | p |
|---|---|---|---|
| T cells | |||
| CD3+ | 69.20 [60.98; 75.33] | 80.0 [72.28; 88.63] | .000** |
| CD3+CD4+ | 40.30 [31.70; 47.40] | 32.0 [24.53; 39.13] | .000** |
| CD4+CD45RA+ | 10.4 [6.70; 15.20] | 4.80 [2.90; 8.30] | .000** |
| CD4+CD45RA− | 24.30 [21.30; 28.90] | 23.0 [17.80; 28.40] | .267 |
| CD4+CD45RO+ | 24.20 [21.10; 29.40] | 23.10 [17.98; 28.40] | .227 |
| CD45RA/CD45RO | 2.80 [2.00; 3.70] | 2.85 [2.00; 3.70] | .599 |
| CD3+CD8+ | 22.05 [17.88; 28.76] | 37.00 [28.48; 47.15] | .000** |
| CD8+CD38+ | 5.35 [3.98; 8.60] | 9.30 [6.20; 13.05] | .000** |
| CD4/CD8 | 1.80 [1.20; 2.30] | 0.90 [0.60; 1.30] | .000** |
| CD19+ B cells | 9.00 [6.78; 11.85] | 6.75 [4.68; 9.05] | .000** |
| CD3−CD56+ NK cells | 16.35 [10.00; 26.50] | 10.00 [6.68; 17.45] | .000** |
| CD3+CD56+ NKT cells | 2.75 [1.78; 4.00] | 3.35 [2.20; 4.23] | .025* |
Data are shown as median [interquartile range] %; Baseline represents before any treatment; Post-CRT represents three months after chemoradiotherapy. *p ≤ 0.05; **p ≤ 0.001